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OBJECTIVES: This study aimed to evaluate the clinical outcomes of intra-articular infiltration with hyaluronic
acid and dexamethasone alone and in combination in the treatment of knee osteoarthritis (OA).
METHOD: This prospective randomized trial evaluated 44 patients undergoing treatment for OA. Patients were
selected through clinical and radiological analysis using the American College of Rheumatology criteria. We
included patients aged between 50 and 70 years who presented with K-L stage p2 knee OA and normal limb
alignment. Patients with a previous history of knee injury (ligamentous, meniscal or traumatic), infection,
patellofemoral OA or chondroprotective drug use in the previous year were excluded. Participants were
randomized into 3 groups and underwent treatment with viscosupplementation (VS, n=16), viscosupplementa-
tion plus dexamethasone (VD, n=16) or dexamethasone (DX, n=12). All patients were evaluated before and
6 weeks, 3 months and 6 months after infiltration. Analysis included a physical examination, the Western
Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire (total score and domain subscores)
and an evaluation of knee extensor and flexor strength and proprioception using an isokinetic dynamometer.
RESULTS: VS significantly improved the WOMAC total score and subscores for pain, stiffness and function for up
to 6 months after infiltration. It also improved knee extensor and flexor strength during the same period.
Proprioception was not affected by any of the treatments.
CONCLUSIONS: VS alone improved pain, stiffness and function according to the WOMAC total score and
subscores and improved knee extensor and flexor strength, but not proprioception, for up to six months after
infiltration. These findings suggest that VS has a positive effect on quadriceps arthrogenic inhibition.
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’ INTRODUCTION
Osteoarthritis (OA) is a degenerative disease that causes
progressive joint pain and disability. Recently, OA was defi-
ned as a disease that involves the synovial joint as a whole
(1). The prevalence of OA is high worldwide, estimated as
3.8% in 2010 (2). Quadriceps strength is reduced 50% in patients
with knee OA (3) and represents a feature of the disease (4).
This occurs partly due to a neural activation deficit of the
quadriceps known as arthrogenic muscle inhibition (5,6).
The conservative treatment of OA involves a set of non-
pharmacological measures, including education, diet, reha-
bilitation, and pharmacological approaches, ranging from
analgesics and anti-inflammatory drugs to infiltration agents,
to promote pain relief, maintain range of motion (ROM), restore
quality of life and slow the natural disease progression (7).
Corticosteroids, in their crystalline form, have been admi-
nistered since the 1950s, yielding great analgesic improve-
ments (8). Their mechanism of action involves altering B and
T cell immune function and inhibiting phospholipase A2 to
decrease the expression of inflammatory cytokines (8). Dexa-
methasone (DX) is a corticosteroid widely used in clinical
practice; at a low dosage, DX exhibits chondroinductive pro-
perties in vitro that could be useful in modifying the course
of OA (10).
Hyaluronic acid (HA) has a structure that allows joint
lubrication and restores the rheological properties of synovial
fluid (11). HA rose as an option for the conservative treat-
ment of OA approximately 20 years ago due to its better
clinical results compared to those of corticosteroids, mainlyDOI: 10.6061/clinics/2019/e1207
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at 4 weeks after infiltration (12-14). Recently, it has been
suggested that the addition of the corticosteroid triamcino-
lone hexacetonide improves the first-week symptom and
function scores of viscosupplementation (VS) (13).
Hence, we hypothesized that HA combined or not with
corticosteroids could help minimize the effects of quadriceps
arthrogenic muscle inhibition in OA patients, as evaluated by
the WOMAC total score and subscores and knee flexor and
extensor proprioception and strength.
The goal of this study was to clinically evaluate the use of
VS with sodium hyaluronate alone and in combination with
DX for arthrogenic quadriceps inhibition in patients with
knee OA.
’ METHODS
This prospective randomized trial was approved by the
Institutional Research Board (CAAE: 24140813.2.0000.5273),
and all patients signed an informed consent form to participate.
Patients
The sample consisted of 44 patients with primary knee OA,
according to the American College of Rheumatology criteria
(15), who were treated in the OA conservative treatment pro-
gram located in the outpatient unit of the Brazilian National
Institute of Traumatology and Orthopedics between January
2014 and December 2014. This outpatient unit receives three
new patients per week, and the study population consisted of
these patients (120 patients). Patients over 50 years of age who
presented with knee pain and radiographic knee OA classified
by Kellgren and Lawrence as stage p2 and normal limb
alignment (3o to 8o valgus) were included in the study. Patients
with a previous history of traumatic injury, infection or
surgery in the same knee were excluded. Patients presenting
positive Lachman, anterior drawer and/or pivot-shift tests,
suggesting knee instability, and positive meniscal tests, sug-
gesting meniscal tear, were also excluded. Finally, we exclu-
ded patients with a body mass index (BMI) over 35 kg/m2,
patients with patellofemoral arthritis, identified on radio-
graphs, and patients who had a history of treatment with
chondroprotective drugs, corticosteroid infiltration or VS in
the previous year (Figure 1).
Clinical procedures
Patients were prospectively selected in the outpatient unit
and designated for clinical evaluation in the clinical research
unit of the institute. In this evaluation, patients received infor-
mation about the research, including the risks and benefits.
The patients who met the eligibility criteria and agreed to
participate signed the informed consent form to be included in
the study. After randomization and group allocation, patients
were interviewed and submitted to clinical evaluation and
infiltration. Patients were evaluated immediately before and
6 weeks, 3 months and 6 months after infiltration. The proto-
col was not registered with any clinical trial platform.
Randomization was performed using blocks of six patients
(two for each group) and sealed envelopes containing the
acronym identifying the groups (VS/VD/DX), which was
opened after completing the clinical evaluation. Infiltration
was performed by a member of the staff (PAVM) who did not
participate in the evaluations. After allocation, the patients
were treated as follows:
1) Viscosupplementation group (VS group): VS alone with
3 doses (6 mL) of sodium hyaluronate 15 mg/mL
(Orthoviscs, Johnson & Johnsons) in a single shot.
2) Viscosupplementation plus dexamethasone group (VD
group): VS with 3 doses (6 mL) of sodium hyaluronate
15 mg/mL (Orthoviscs, Johnson & Johnsons) plus 1 dose
of DX (4 mg/1 mL) in a single shot.
3) Dexamethasone group (DX group): 1 dose of DX (4 mg/
1 mL) in a single shot.
Evaluations were performed by other members of the staff
who did not participate in the infiltration procedures (EBS
and VRAC). Infiltration was performed with the patient
seated and knees flexed through anterolateral access to the
knee. To evaluate arthrogenic quadriceps inhibition, the pro-
tocol included clinical, proprioception and knee extensor and
flexor strength evaluations.
Clinical evaluation
Age (in years), laterality (right/left, self-reported by
preferred limb to kick a ball regardless of the influence of
OA), weight (in kilograms), height (in meters), BMI (kg/m2),
knee joint ROM and lower limb alignment were recorded in
the clinical evaluation.
Radiographic analysis included a standing full-length lower
extremity, an anteroposterior (AP) and lateral view of the knee
joint to stratify the OA severity according to the Kellgren-
Lawrence classification and measurement of the lower limb
mechanical axis.
The subjective functional evaluation used the Western
Ontario McMaster Universities Osteoarthritis Index (WOMAC)
questionnaire validated for the Portuguese language (16),
including the total score and its subscores for the pain,
stiffness and function domains.
Proprioception evaluation
The knee proprioception evaluation involved sensing of
the joint position. An isokinetic dynamometer (CSMI, Humac
Norm) was used in all of these procedures. All tests were
conducted with the subject in a seated position with the hip at
approximately 90o and the entire back touching the backrest.
The patient was fixed to the seat by means of a belt.
First, the subject was required to experience and then
reproduce joint positions, through voluntary movements inFigure 1 - Study flow diagram.
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both cases. Two target positions were used: 20% and 50%
of the flexion–extension (FLEX–EXT) ROM (0%=maximum
extension). Throughout the procedure, the patient was blind-
folded. Variations of ±5o around the target position were
allowed. If this margin was violated, the trial was discarded,
and a new attempt was made. A total of 10 trials were perfor-
med, and 5 were chosen randomly for each target position.
The individual error value for each attempt was determined
through the difference between the position reproduced and
the position experienced. The proprioceptive performance
was determined with the absolute error (AE), obtained
through the arithmetic mean of the absolute values of indivi-
dual errors. The commands for carrying out the task were
issued verbally by the evaluator, and the direction of move-
ment was always from flexion to extension. During the
procedure, the subject was blinded with special goggles to
attenuate visual bias.
Knee extensor and flexor strength evaluation
After 10 minutes of rest, the strength evaluation was
carried out. Prior to each test, all calibration procedures were
accomplished, and the participant performed a warm-up
familiarization process comprising movements of knee
extension and flexion at submaximal effort. Each test consis-
ted of one set of five repetitions in the isokinetic concentric-
concentric mode at an angular speed of 60o/s, and only the
involved limb was evaluated. The maximum value found
was defined as the peak torque (PT), which was normalized
by the subject’s weight and recorded for statistical proposes.
Statistical analysis
The results are presented as the mean and standard devi-
ation (SD). For the WOMAC scores, comparisons were made
within groups by one-way ANOVA at each measurement
time point (PRE, 6 W, 3 M and 6 M). The dependent variables
were PT EXT, PT FLEX, AE20 (absolute error at 20% of
FLEX–EXT ROM), AE50 (absolute error at 50% of FLEX–EXT
ROM), and the WOMAC total score and pain, stiffness and
physical activity subscores. The Shapiro-Wilk test showed all
variables to be normally distributed (all, p40.05). To com-
pare demographic data (height, weight, BMI, and age), one-
way ANOVA was used. First, one-way repeated measures
ANOVA was used to compare within-subject effects over
time (PRE, 6 W, 3 M, and 6 M) and between-treatment effects
(DX, VD and VS). When a significant within-main effect was
observed, one-way ANOVA was performed again for each
group separately. If sphericity could not be assumed, the
Greenhouse-Geisser correction was applied. Pairwise post
hoc comparisons were carried with Bonferroni’s test. To pre-
serve the repeated measures design if any evaluation session
throughout the study was lost, the respective subject
́
s data
were withdrawn from the analysis. The effect size was
assessed by Zp
2 and classified as small=0.01, medium=0.06, or
large=0.14 (17). All calculations were conducted using IBM
SPSS software for Windows (EUA) and graphics produced
with GraphPad Prism (EUA). The significance level was
set at 0.05.
’ RESULTS
Clinical data
Initially, forty-four patients were included in the study,
and the demographic data are presented in Table 1. There
were no significant differences regarding the demographic
data, except for height, which was greater in the DX group
than in the VD group.
Statistically significant effects were observed over time
regarding the WOMAC total score and pain, stiffness and
physical activity subscores (all, po0.05). Additionally, signi-
ficant effects between groups were observed in the pain
(p=0.03, Zp
2=0.24), stiffness (p=0.03, Zp
2=0.28), physical activity
(p=0.03, Zp
2=0.26) subscores, but not in the total score (p=0.07,
Zp
2=0.18). Pairwise verification demonstrated a difference
between the DX and VS groups. Further separate analysis
revealed significant differences only within the VS group
regarding the pain (p=0.01, Zp
2=0.39), stiffness (p=0.04, Zp
2=0.29),
and physical activity (p=0.05, Zp
2=0.33) subscores and the total
score (p=0.03, Zp
2=0.37) (Figure 2 and Table 2).
Proprioception evaluation
There were no significant differences in either the AE20
(within p=0.30, Zp
2=0.04; between p=0.20, Zp
2=0.20) or the
AE50 (within p=0.35, Zp
2=0.04; between p=0.036, Zp
2=0.21)
(Figure 3A). General analysis of the AE50 revealed a sig-
nificant effect between groups. However, pairwise compar-
isons did not identify significant differences (Figure 3B).
Strength evaluation
We found no significant differences in PT EXT (Figure 4A)
in any of the groups over time (p=0.07, Zp
2=0.10). However,
when the groups were compared, differences were identified
(p=0.02, Zp
2=0.28). Moreover, pairwise differences were obser-
ved between DX and VD (p=0.03) and between DX and VS
(p=0.04). Regarding PT FLEX (Figure 4B), a significant main
effect was observed over time (p=0.01, Zp
2=0.16) and between
groups (p=0.02, Zp
2=0.26). A pairwise significant difference
was observed between DX and VD (p=0.03), but not between
DX and VS (p=0.07). Further separate analysis revealed a
significant difference in both PT EXT (p=0.03, Zp
2=0.31) and
PT FLEX (p=0.03, Zp
2=0.54) only for VS.
Adverse effects
None of the patients included in the study presented
adverse effects.
’ DISCUSSION
Arthrogenic quadriceps inhibition is present in patients
with knee OA and is associated with joint inflammation,
pain, and swelling, contributing to muscle atrophy and hind-
ering rehabilitation (6). We hypothesized that HA alone
or in combination with corticosteroids could help minimize
Table 1 - Demographic characteristics of patients included in
the study. Demographic data of patients in each group.
Demographic data
DX VS VD
Patients (n, F:M) 12 (11:1) 16 (10:6) 16 (10:6)
Laterality (R/L) 9/3 10/6 7/9
Height (m) 156.7±1.98 1.63±3.2 165.6±2.2*
Weight (kg) 76.8±3.9 86.5±4.9 79.3±3.2
BMI (kg/m2) 31.4±1.8 31.9±1.3 29.0±1.2
Age (years) 60.3±1.7 56.6±1.0 54.5±2.4
DX: dexamethasone; VS: viscosupplementation; VD: visco-
supplementation plus dexamethasone, BMI: body mass index,
F: female; M: male; R: right; L: left. *po0.05 vs. DX group.
3
CLINICS 2019;74:e1207 Viscosupplementation in knee osteoarthritis
Maia PAV et al.
quadriceps muscle arthrogenic inhibition and help improve
the nonoperative treatment of knee OA.
We designed a prospective randomized trial to compare
the use of DX and HA alone and in combination in the
treatment of knee OA by evaluating the WOMAC total score
and subscores and knee extensor and flexor strength and
proprioception. Our results show that VS alone significantly
improved pain, stiffness and function, as shown by the
WOMAC subscores. In addition, VS alone improved knee
extensor and flexor strength, but not proprioception.
Intra-articular corticosteroid use is criticized because of its
short analgesic effect, which lasts for up to approximately
one month after infiltration (18), in addition to not having
any modifying effect on the disease. Nevertheless, its use is
recommended in many protocols for OA treatment (19). HA
reestablishes the ideal rheological properties of synovial
fluid but may cause synovitis after infiltration and does not
produce an immediate analgesic effect; however, it is more
effective in the long term, with effects lasting up to six
months (18). Nevertheless, a study confirmed its efficacy by
Figure 2 - WOMAC score evaluation. Significant effects were observed over time in the WOMAC total score and pain, stiffness and
physical activity subscores (all, po0.05). Additionally, significant effects between groups were observed in the pain (p=0.03), stiffness
(p=0.03), and physical activity (p=0.03) subscores, but not in the WOMAC total score (p=0.07). Pairwise verification demonstrated
differences between DX and VS. Further separate analysis revealed significant differences only within the VS group in terms of the pain
(p=0.01), stiffness (p=0.04), and physical activity (p=0.05) subscores and the WOMAC total score (p=0.03). Symbols represent mean
values, dashed and straight lines represent standard deviations. 6 W: six weeks, 3 M: three months and 6 M: six months; a: compared to
PRE; b: compared to 6 W; c: compared to 3 M; d: compared to 6 M.
Table 2 - WOMAC questionnaire data. Data from the WOMAC questionnaire were divided into the score for three domains (pain,
stiffness and function) and the total score for all three groups.
Group PRE 6 W 3 M 6 M F-value p-value g2p
WOMAC - Pain
VS 15.3 (2.8) 14.4 (3.5) 14.3 (3.6) 15.4 (2.6) 5.09 0.01 0.39
VD 12.4 (4.9) 9.9 (5.7) 11.6 (5.9) 11.7 (6.0) 0.83 0.46 0.08
DX 12.8 (3.8) 7.1 (3.8) 7.1 (3.9) 11.3 (6.2) 0.14 0.93 0.02
WOMAC - Stiffness
VS 7.3 (3.2) 5.5 (2.0) 7.0 (3.1) 6.3 (1.4) 3.22 0.04 0.29
VD 4.6 (1.9) 4.4 (2.7) 5.6 (2.6) 3.9 (2.6) 0.15 0.15 0.18
DX 5.9 (1.1) 3.4 (2.4) 3.8 (2.6) 3.7 (1.9) 1.17 0.34 0.16
WOMAC - Physical Activity
VS 52.4 (5.8) 45.1 (11.0) 49.3 (7.7) 54.1 (11.4) 3.90 0.02 0.34
VD 44.1 (14.8) 35.7 (19.1) 41.9 (20.5) 37.0 (22.7) 2.26 0.15 0.18
DX 42.4 (14.1) 23.2 (13.3) 26.1 (16.3) 33.8 (21.5) 1.17 0.34 0.16
WOMAC - Total
VS 68.4 (18.3) 59.4 (21.3) 67.4 (15.9) 73.5 (15.4) 4.71 0.03 0.37
VD 61.1 (21.1) 50.0 (27.2) 59.0 (28.4) 52.6 (31.1) 1.04 0.34 0.09
DX 61.1 (16.9) 33.8 (19.1) 37.6 (23.1) 48.8 (28.0) 1.08 0.37 0.15
DX: dexamethasone; VS: viscosupplementation; VD: viscosupplementation+ dexamethasone; PRE: before treatment; 6 W: six weeks after treatment; 3 M:
three months after treatment; 6 M: 6 months after treatment. Values are shown as the mean (SD). Significant differences are in bold.
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reporting a reduction in pain of more than 50% in most
patients treated with infiltration (20). The association between
corticosteroids and HA has been recently explored to enhance
the clinical results of each drug class (13).
One study showed significant improvement in knee pain
and function in patients treated with HA infiltration com-
pared to placebo at five weeks after treatment. However,
these effects lasted only until the 25th week after infiltration
(14,21-22). Another study used three different kinds of HA in
women between 40 and 60 years old with moderate knee OA
or degenerative meniscal tear, and similar to our study, the
study concluded that HA is in fact the best conservative
treatment for these patients (23). Major efficacy of HA was
confirmed at 8 weeks after infiltration in a systematic review
including 7 studies with 606 patients (24). Another rando-
mized and double-blind study with 51 patients verified
that the clinical effects of HA and corticosteroids as a local
therapy are comparable and that both are useful for the
conservative treatment of OA (25). In our study, three doses
of isolated HA in a single shot improved knee pain, stiffness
and function as evaluated by the WOMAC total score and
subscores. In addition, knee extensor and flexor strength was
increased for up to six months in patients who received
HA infiltration alone. We believe this was due to pain
reduction, which allowed patients to perform rehabilitation
appropriately. However, we found no differences in proprio-
ception parameters.
The use of a single shot of HA or methylprednisolone in
patients with mild OAwas compared. Similar clinical results
were observed between the groups, but HA showed superior
analgesic effects after the 12th week (26). However, in a
multicentric, double-blind, randomized study evaluating 391
patients, HA presented no analgesic superiority over corti-
costeroids (22). The effects of VS with Hylan G-F 20 and
triamcinolone alone and in combination were also compared.
In one study, this combination improved pain, mainly in the
first week after infiltration (9), while in another study, the
improvements in the functional scores lasted up to three
months (27). Another study involving 47 patients showed
that the same combination improves subjective pain and
function (28). In the same way, another clinical study demon-
strated similar analgesic improvement through a combina-
tion of corticosteroids and HA compared to HA alone. In
addition, magnetic resonance imaging did not detect radio-
graphic progression of the disease during the study period in
either group (29). In this study, three doses of isolated HA in
a single shot improved knee pain, stiffness and function, as
indicated by the WOMAC scores. In addition, knee extensor
and flexor strength was increased for up to six months in
patients who received infiltration with HA alone. We believe
Figure 3 - Proprioception evaluation. A. Absolute error 20%. There were no significant differences regarding the AE20 over time
(p=0.30) or between groups (p=0.20). B. Absolute error 50%. The same results were found for the AE50 over time (p=0.35). General
analysis showed a significant difference between groups (p=0.036), which was not confirmed by pairwise comparison.
Figure 4 - Strength evaluation. A. Knee extensor peak torque. No significant differences regarding PT EXT over time (p=0.07) were
identified. Analysis between groups presented significant differences (p=0.02). Pairwise differences were observed between DX and VD
(p=0.027) and between DX and VS (p=0.043). B. Knee flexor peak torque. Regarding PT FLEX, significant main effects were observed
both over time (p=0.01) and between groups (p=0.02). A pairwise significant difference was observed for DX and VD (p=0.034), but not
for DX and VS (p=0.067). Further separate analysis revealed significant differences in both PT EXT (p=0.03) and PT FLEX (p=0.03) only in
the VS group. Symbols represent mean values, dashed and straight lines represent standard deviations. 6 W: six weeks, 3 M: three
months and 6 M: six months; a: compared to PRE; b: compared to 6 W; c: compared to 3 M; d: compared to 6 M.
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this was due to pain reduction, which allowed patients to
perform rehabilitation appropriately. However, we found no
differences in proprioception parameters.
Initially, it was demonstrated that proprioception was
affected by knee OA and that HA infiltration did not nega-
tively affect proprioception (30). Then, in a prospective,
randomized, placebo-controlled trial involving 63 patients
with grade II-III knee OA, an increase in isokinetic strength
and proprioception after infiltration with Hylan G-F 20 was
demonstrated (31). Finally, another study including patients
between 50 and 70 years old with bilateral knee OA verified
an increase in postural stability and a decrease in the risk of
fall in patients treated with HA infiltration compared to
worsening conditions in those who received the placebo (32).
It has been previously demonstrated that aspirating joint
effusion and/or injecting a local anesthetic into the joint
abolishes arthrogenic muscle inhibition (33-34). Therefore,
we hypothesized that injecting corticosteroids alone or in
combination with HA could have the same clinical effect.
Our data indicate improvement in knee extensor and flexor
strength lasting for up to six months in patients treated with
HA alone and in knee extensor strength in patients treated
with HA combined with DX. The magnitude of this effect
was greater in the HA group, which confirmed our hypo-
thesis that HA could modulate arthrogenic inhibition in
patients with knee OA.
The importance of strength training has been widely
proven, with the consequent development of strength (35-36)
and proprioception in patients with OA (36). Healthy knees
and knees in early stages of OA present greater quadriceps
and hamstring strength than those in late stages of the disease
(37). Hence, quadriceps strength training could reduce pain
and increase proprioception, reinforcing the importance of
muscle strength training in patients with knee OA (38). Simi-
larly, a metanalysis concluded that proprioception exercises
are effective in the conservative treatment of knee OA (39).
The main strength of this study is that we compared knee
OA treatment using VS alone, VS combined with corticoster-
oids and corticosteroids alone using the same protocol. More-
over, the evaluation was performed using not only scores but
also the findings of knee flexor and extensor strength and knee
proprioception evaluations performed using an isokinetic
dynamometer.
The limitations of the study include the small sample
number and the availability of rehabilitation for the patients
included in the study. All patients received guidance regard-
ing the rehabilitation protocol to which they should have
access, considering the protocol used in our institution and
those available in our public health system. There is a lack of
scientific evidence in the literature regarding the effect of HA
on patellofemoral OA. Thus, these patients were excluded to
avoid misinterpretation of the data.
In conclusion, according to our results, VS alone improved
pain, stiffness and function according to the WOMAC total
score and subscores for up to six months after infiltration. VS
also improved knee extensor and flexor strength in the same
period, but not proprioception. These findings suggest that
VS has a positive effect on quadriceps arthrogenic inhibition.
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